FOXA1 mutations dysregulated estrogen-ER activity (Figure 2B) and were associated with worse outcome for metastatic ER + breast cancer (Hurtado et al., 2011; Arruabarrena-Aristorena et al., 2020). The gene discussed is FOXA1; the disease is breast carcinoma.